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Differential regulation by AMP and ADP of AMPK complexes containing
different γ subunit isoforms
Fiona A. Ross*, Thomas E. Jensen† and D. Grahame Hardie*1
*Division of Cell Signalling & Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, U.K.
†Department of Nutrition, Exercise and Sports, University of Copenhagen, Universitetsparken 13, 2100 Copenhagen, Denmark
The γ subunits of heterotrimeric AMPK complexes contain the
binding sites for the regulatory adenine nucleotides AMP, ADP
and ATP. We addressed whether complexes containing different
γ isoforms display different responses to adenine nucleotides by
generating cells stably expressing FLAG-tagged versions of the
γ 1, γ 2 or γ 3 isoform. When assayed at a physiological ATP
concentration (5 mM), γ 1- and γ 2-containing complexes were
allosterically activated almost 10-fold by AMP, with EC50 values
one to two orders of magnitude lower than the ATP concentration.
By contrast, γ 3 complexes were barely activated by AMP under
these conditions, although we did observe some activation at
lower ATP concentrations. Despite this, all three complexes were
activated, due to increased Thr172 phosphorylation, when cells
were incubated with mitochondrial inhibitors that increase cellular
AMP. With γ 1 complexes, activation and Thr172 phosphorylation
induced by the upstream kinase LKB1 [liver kinase B1; but
not calmodulin-dependent kinase kinase (CaMKKβ)] in cell-
free assays was markedly promoted by AMP and, to a smaller
extent and less potently, by ADP. However, effects of AMP
or ADP on activation and phosphorylation of the γ 2 and γ 3
complexes were small or insignificant. Binding of AMP or ADP
protected all three γ subunit complexes against inactivation by
Thr172 dephosphorylation; with γ 2 complexes, ADP had similar
potency to AMP, but with γ 1 and γ 3 complexes, ADP was less
potent than AMP. Thus, AMPK complexes containing different
γ subunit isoforms respond differently to changes in AMP, ADP
or ATP. These differences may tune the responses of the isoforms
to fit their differing physiological roles.
Key words: adenine nucleotides, adenosine 5′-diphosphate
(ADP), adenosine 5′-phosphate (AMP), adenosine 5′-phosphate
(AMP)-activated protein kinase (AMPK), adenosine
5′-triphosphate (ATP).
INTRODUCTION
AMP-activated protein kinase (AMPK) is expressed ubiquitously
and is activated by increases in AMP and/or ADP relative
to ATP, thus acting as a sensor of cellular energy status
[1–3]. Once activated by cellular stress it acts to restore
energy homoeostasis by switching on ATP-producing catabolic
pathways, while switching off anabolic pathways and other ATP-
consuming processes. AMPK occurs universally in eukaryotes as
heterotrimeric complexes comprising a catalytic α subunit and
regulatory β and γ subunits; in humans, all three subunits are
encoded by multiple genes, i.e. PRKAA1 and PRKAA2, encoding
α1 and α2; PRKAB1 and PRKAB2, encoding β1 and β2; and
PRKAG1–PRKAG3, encoding γ 1, γ 2 and γ 3 [4–6]. All 12
possible combinations of subunits can form complexes when
co-expressed [7], although certain combinations appear to be
favoured in specific tissues [8]. AMPK complexes are activated
by upstream kinases that phosphorylate a conserved threonine
residue (Thr172 in rat α2 [9]) within the activation loop of the
α subunit kinase domain. Upstream kinases that phosphorylate
Thr172 include the tumour suppressor LKB1 (liver kinase B1)
[10–12] and the Ca2 + /calmodulin-dependent kinase, calmodulin-
dependent kinase kinase (CaMKK)β [13–15]. The β subunits
contain conserved domains called carbohydrate-binding modules
(CBMs), related to domains found in enzymes that bind starch
or glycogen. One surface of the CBM causes cellular AMPK
complexes to bind to glycogen particles [7,16,17], whereas the
opposite surface associates with the N-terminal lobe of the kinase
domain, with the cleft between them forming the binding site
for synthetic activators of AMPK, such as 991 and A-769662
[18] and the natural activator salicylate [19,20]. A-769662 can
cause a dramatic allosteric activation (>60-fold) of AMPK even
when it is not phosphorylated on Thr172 [21]. The γ subunits of
AMPK contain four tandem repeats of a sequence motif termed a
cystathionine-β-synthase (CBS) repeat [22,23]. These assemble
in a pseudo-symmetrical manner to form a disc-like shape with
one repeat in each quadrant, generating two potential ligand-
binding clefts between repeats 1 and 2 and two between repeats
3 and 4 [24] (binding sites are numbered according to the CBS
repeat interacting with the ribose ring of the bound nucleotide
[25]). However, one site (site 2) appears to be unused, whereas an-
other (site 4) is thought to be permanently occupied by AMP [24]
(although this has been challenged [26]). The remaining two (sites
1 and 3) bind AMP, ADP or ATP in a competitive manner [24,27].
AMP binding activates AMPK by three effects: (i) promotion
of Thr172 phosphorylation by LKB1; (ii) inhibition of Thr172
dephosphorylation by protein phosphatases; and (iii) allosteric
activation [28]. Binding of ATP inhibits AMPK by antagonizing
the binding of AMP without causing any of the activating effects,
whereas binding of ADP has been reported to mimic two of the
effects of AMP, i.e. (i) [29] and (ii) [27], although not allosteric
activation (iii). Using native AMPK purified from rat liver, our
group recently reported that ADP mimicked the effect of AMP to
inhibit Thr172 dephosphorylation [effect (ii)], but we were unable
Abbreviations: ACC, acetyl-CoA carboxylase (ACC); AICAR, 5-aminoimidazole-4-carboxamide riboside; AMPK, AMP-activated protein kinase; CaMKK,
calmodulin-dependent kinase kinase; CBM, carbohydrate-binding module; CBS, cystathionine-β-synthase; IP, immunoprecipitate; LKB1, liver kinase B1;
PP1γ, protein phosphatase-1 catalytic subunit.
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to discern any effect of ADP on Thr172 phosphorylation [effect
(i)]. We also found that AMP was almost 10-fold more potent
than ADP in inhibiting Thr172 dephosphorylation, suggesting that
AMP may remain as the crucial signal [28].
Although the existence of multiple isoforms of the AMPK-
α, -β and -γ subunits has been known for many years [4–6],
the question of whether the different isoform combinations have
distinct functions remains only partially answered. The α2 subunit
is found in various cell types to be more enriched in the nucleus
than the α1 subunit [30–32], although both contain well-defined
nuclear export signals at their C-termini [33]. The CBM of the
β2 subunit appears to have a higher affinity for glycogen than
that of β1 [34] and to bind more tightly to glycogen particles in
intact cells [7]. The greatest sequence variability occurs within
the γ subunit isoforms; γ 2 and γ 3 contain long N-terminal
extensions that are unrelated to each other and are absent from
γ 1, although both can also occur as shorter variants due to the
use of different transcriptional start sites [35,36]. Although
the exact functions of these N-terminal extensions remain unclear,
it is tempting to propose that they target AMPK complexes
to different subcellular locations, and there is indeed some
evidence that different isoform combinations are found at
different locations [30,35,37]. The γ 3 isoform is only thought
to be expressed significantly in skeletal muscle [5,36], where
it forms a complex preferentially with the α2 and β2 isoforms
[8]. Previously, we reported that the AMPK activator PT-1
activates γ 1- but not γ 3-containing complexes in mouse skeletal
muscle, whereas the nucleoside AICAR (5-aminoimidazole-4-
carboxamide riboside), which is taken up into cells and converted
into an AMP analogue [38], activated both isoforms. In contrast
with AICAR, PT-1 did not promote glucose uptake, consistent
with previous findings in knockout mice suggesting that the
γ 3 complex is required for effects of AMPK on glucose
uptake [39]. These results initially suggested that PT-1 was
a selective activator of AMPK complexes containing the γ 1
rather than the γ 3 isoform. However, when we stably expressed
FLAG-tagged human γ 1, γ 2 or γ 3 in HEK-293 cells and
immunoprecipitated the different γ isoform complexes using
anti-FLAG antibodies, we found that all three complexes were
activated by PT-1. We also found, in contrast with previous
proposals [40], that PT-1 activated AMPK by inhibiting the
respiratory chain and thus increasing cellular AMP. Thus,
the selectivity for γ 1 over γ 3 complexes in skeletal muscle must
be a specific feature of that cell type, most probably because PT-
1 does not increase AMP in the cell compartment in which γ 3
complexes are located.
Having constructed human embryonic kidney (HEK)-293 cells
expressing FLAG-tagged human γ 1, γ 2 or γ 3 for this previous
study, we decided to make use of them to examine whether there
was any differential regulation of AMPK complexes containing
different γ subunit isoforms by adenine nucleotides.
EXPERIMENTAL
Materials and proteins
Berberine chloride, phenformin and A23187 were from Sigma–
Aldrich. A769662 was synthesized as described previously [41].
Recombinant human CD73 was from R&D Systems. Human
CaMKKβ was expressed as a GST-fusion and purified from
Escherichia coli [15]. Human LKB1–STRAD (Ste20 related
adaptor)–MO25 (mouse protein-25) complex was expressed in
an insect cell baculovirus system [42]. PP2Cα was expressed in
E. coli and purified as described in [43]. Protein phosphatase-1
catalytic subunit (PP1γ ) was expressed in E. coli as a GST-fusion
protein. Polycistronic bacterial expression plasmids encoding the
human α1β1γ 1, α2β2γ 1 and α2β2γ 3 complexes of AMPK
were gifts from the Division of Signal Transduction Therapy
(University of Dundee), AstraZeneca and Pfizer respectively.
They were purified using the N-terminal His6-tags on the
α subunits, as described previously [19].
Antibodies
The anti-pThr172, -β1, -pan-α and -glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) antibodies were from Cell Signaling
Technology. Antibodies against the FLAG epitope were from
Sigma–Aldrich. The anti-γ 1 antibody was from Abcam and
the anti-α1, -α2 [44], -β2 [5], -γ 2 and -γ 3 [6] antibodies
were described previously. Secondary anti-rabbit and anti-sheep
immunoglobulin antibodies were from Li-Cor Biosciences.
Generation of stable cell lines expressing human γ 1, γ 2 and γ 3
HEK-293 cells expressing tetracycline-inducible human γ 1, γ 2
and γ 3 with N-terminal FLAG tags were obtained by inserting
the appropriate DNA into cells carrying a Flp recombinase target
site with co-transfection of DNA encoding Flp recombinase;
expression of the γ subunits was induced by adding tetracycline
(1 μg·ml− 1) to the medium for 48 h [39,45].
Cell culture
HEK-293 cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM) containing 4.5 g/l glucose, 10% (v/v) FBS,
100 units/ml penicillin, 100 μg/ml streptomycin, 200 μg/ml
hygromycin and 15 μg/ml blasticidin. The medium was replaced
with medium containing 1 g/l glucose, 16 h before the treatments
described in the text.
AMPK assays in cell lysates
Cell lysates were made using the rapid lysis procedure [46].
Lysates containing stably expressed recombinant FLAG-tagged
γ subunits were immunoprecipitated from HEK-293 cell lysates
(90 μg of lysate protein) by incubation at 4 ◦C for 2 h on
a roller mixer with 7.5 μl of EZview Red anti-FLAG M2
affinity gel (Sigma–Aldrich). After extensive washing, the
immunoprecipitates (IPs) were assayed for AMPK activity on
an orbital shaker as described previously [46,47] except that the
AMARA peptide substrate [48] was used in all assays apart from
those shown in Figures 3 and 4. The SAMS peptide was used in
the latter because, for reasons that remain unclear, the degree of
allosteric activation is always greater using this substrate.
Allosteric activation of immunoprecipitated γ complexes
AMPK was activated by incubating the cells in phenformin
(10 mM) for 60 min prior to cell lysis. Cell lysates (360, 360
and 560 μg of lysate protein for γ 1, γ 2 and γ 3 respectively)
were incubated with 50 μl of EZview Red anti-FLAG M2 affinity
gel and immunoprecipitated and washed as described previously
[49]. The final precipitates were resuspended in 2 ml of Hepes
assay buffer (50 mM sodium Hepes, pH 7.4, 1 mM DTT, 1 mM
EDTA and 0.02% Brij-35) and divided into 20 100-μl aliquots.
AMPK activity was assayed for 10 min using SAMS peptide, with
concentrations of AMP and ATP specified in figures and figure
legends. MgCl2 was kept at a constant 4.8 mM excess over the
concentration of ATP.
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Promotion of activation and Thr172 phosphorylation by AMP and
ADP
Cell lysates (140, 500 and 2000 μg of lysate protein for γ 1, γ 2
and γ 3 respectively) were incubated with 100 μl of EZview Red
anti-FLAG M2 affinity gel, immunoprecipitated and washed as
described previously [49]. The IPs were resuspended in 100 μl
of Hepes assay buffer and incubated in an orbital incubator with
PP1γ (55 μg in 10 μl) in Hepes assay buffer for 30 min at 30 ◦C.
The dephosphorylation reactions were stopped by washing the
IPs three times in Hepes assay buffer. The precipitates were then
resuspended in 1 ml of Hepes assay buffer [46] and divided into
100-μl aliquots. After centrifugation, 75 μl of each supernatant
was removed, 5 μl of okadaic acid (final concentration 25 μM)
was added and incubation continued for 5 min at 30 ◦C. After this,
AMP or ADP and LKB1 were added as specified and the reaction
started by adding a mixture of MgCl2 (final concentration 9.8 mM)
and ATP (final concentration 5 mM). Incubation was for 10 min
at 30 ◦C, after which the reactions were stopped by washing the
IPs three times in Hepes assay buffer. They were resuspended in
400 μl of assay buffer and split for assays and analysis by Western
blotting.
Protection against inactivation and Thr172 dephosphorylation by
AMP and ADP
AMPK was activated by incubating the cells in phenformin
(10 mM) for 60 min prior to cell lysis. Cell lysates (225, 225 and
455 μg of lysate protein for γ 1, γ 2 and γ 3 respectively) were
incubated with 100 μl of EZview Red anti-FLAG M2 affinity gel
beads at 4 ◦C for 2 h on a roller mixer. The beads were washed
twice with 1 ml of immunoprecipitation buffer and twice with
1 ml of Hepes assay buffer [46], resuspended in 1 ml of assay
buffer and divided into 100-μl aliquots. The beads were recovered
by centrifugation and 75 μl of the supernatant removed. In a
final volume of 50 μl, AMP, ADP (as specified), ATP (5 mM)
and PP2Cα (1.5 μg) were added and the reaction was started
by adding MgCl2 (9.8 mM) to activate PP2Cα; the reactions
were then conducted in a shaking incubator at 30 ◦C for 10 min.
They were stopped by washing the beads three times in assay
buffer, resuspending them in 400 μl of assay buffer and dividing
them into aliquots for kinase assays and analysis by Western
blotting.
Western blotting and other analytical procedures
For analysis of proteins, SDS/PAGE was performed using precast
Novex NuPAGE Bis-Tris 4–12% gradient polyacrylamide gels in
the MOPS buffer system (Invitrogen). Proteins were transferred
on to nitrocellulose membranes using the IBlot system (Life
Technologies) and blocked in Li-Cor Odyssey blocking buffer
for 1 h, and detection was performed using the appropriate
secondary antibody coupled to IR680 or IR800 dye. Membranes
were scanned using the Li-Cor Odyssey IR imager. For analysis
of immunoprecipitations, membranes were sensitized using
SuperSignal Western Blot Enhancer (Thermo Scientific) before
blocking with Li-Cor Odyssey blocking buffer.
Statistical analysis
Statistical significance was tested using GraphPad Prism 6, using
tests for significance as specified in figure legends.
Figure 1 Characterization of HEK-293 cells stably expressing FLAG-tagged
AMPK-γ 1, -γ 2 or -γ 3 subunits and of immunoprecipitated complexes
(A) Western blots of duplicate cultures of parental HEK-293 cells and cells expressing
FLAG-tagged human AMPK-γ 1, -γ 2 or -γ 3 subunits. Note that FLAG–γ 1 has a slightly lower
mobility on SDS/PAGE than the endogenous γ 1; this effect is less obvious with endogenous
γ 2/FLAG–γ 2 due to their higher molecular mass. The FLAG-tagged γ 1, γ 2 and γ 3 subunits
detected using the anti-FLAG antibody have markedly different mobilities due to their different
molecular masses. (B) Western blots of duplicate IPs made using anti-FLAG antibodies from
HEK-293 cells expressing FLAG-tagged human AMPK-γ 1, -γ 2 or -γ 3 subunits. To correct for
the different levels of expression of γ 1, γ 2 and γ 3, 25, 15 and 50 μg respectively of lysate
protein were loaded.
RESULTS
Characterization of cell lines expressing human γ 1, γ 2 or γ 3
We first characterized the HEK-293 cells stably expressing FLAG-
tagged human γ 1, γ 2 or γ 3 by Western blotting. Figure 1(A)
shows that, after tetracycline induction, the FLAG-tagged γ
subunits partially, but not completely, replaced the endogenous
γ 1 subunit. The expression of endogenous γ 1 (which migrates
slightly faster on SDS/PAGE than FLAG–γ 1) decreased in the
cells expressing FLAG–γ 1 and FLAG–γ 2, although the effect
was less obvious in the cells expressing FLAG–γ 3, which was
expressed at lower levels as judged by the anti-FLAG blots.
The expression of endogenous γ 2 was also slightly decreased
in the cells expressing FLAG–γ 1 and FLAG–γ 3, although the
expression of endogenous α1, α2, β1 or β2 did not change.
Coomassie Blue staining was not sufficiently sensitive to
assess the composition of the γ 1, γ 2 or γ 3 complexes that we
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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immunoprecipitated using anti-FLAG antibodies, but we analysed
them using Western blotting (Figure 1B). They each contained
the expected γ subunit isoform, together with the same relative
proportions of α1 and α2 and β1 and β2, suggesting that the
different γ subunit isoforms did not show any selectivity in
binding to α and β isoforms. The Western blotting data cannot be
used to assess the absolute proportions of α1 compared with α2
or β1 compared with β2 in each complex. However, based on the
AMPK activities of IPs made from the parental HEK-293 cells
using anti-α1, -α2, -β1 and -β2 antibodies, we found that α1
contributed 95 +− 0.2% and α2 contributed 5 +− 0.2%, whereas
β1 contributed 32 +− 2% and β2 contributed 68 +− 2%, of total
kinase activity (means +− S.E.M., n = 4). Thus, HEK-293 cells
primarily express α1, whereas β1 contributes approximately one-
third and β2 approximately two-thirds of total AMPK activity in
these cells.
AMPK-γ 1, -γ 2 and –γ 3 complexes are all activated by Thr172
phosphorylation in intact cells
Figure 2 shows that treatment with phenformin and another
respiratory chain inhibitor, berberine, activated γ 1-, γ 2- and
γ 3-containing complexes and increased their phosphorylation
on Thr172, with the largest effects being on the γ 2 complex.
The Ca2 + ionophore A23187, which activates the alternative
upstream kinase CaMKKβ, also activated and caused Thr172
phosphorylation with all three complexes, although in this case
the largest effects were on the γ 3 complex (whose activation
by A23187 was indeed mediated by CaMKKβ, because it was
completely blocked by the CaMKK inhibitor STO-609 [50];
results not shown). By contrast, A-769662 caused only modest
increases in AMPK activation and Thr172 phosphorylation with
the γ 2- and γ 3-containing complexes and did not significantly
activate γ 1-containing complexes. The latter observation is
similar to previous data obtained using rat hepatocytes (which
express almost exclusively the γ 1 isoform), where there was a
marked phosphorylation of the downstream target acetyl-CoA
carboxylase (ACC) despite the fact that any increases in Thr172
phosphorylation were negligible [51]. The lack of increased
AMPK activation and Thr172 phosphorylation in response to
A-769662, which binds at a different site from AMP [18,51],
suggests that its major effect is on allosteric activation, with only
a small secondary effect on Thr172 dephosphorylation.
Allosteric activation of AMPK complexes containing γ 1, γ 2 or γ 3
We next addressed the allosteric activation of complexes contain-
ing the different γ isoforms, using AMPK immunoprecipitated
from HEK-293 cell stably expressing FLAG-tagged γ 1, γ 2 or γ 3.
These assays were initially performed both at the standard (but
sub-physiological) ATP concentration of 200 μM (Figure 3A)
and at the more physiological ATP concentration of 5 mM
(Figure 3B). In all cases, the AMPK complexes were activated
at low concentrations of AMP due to binding at the γ subunit
and then inhibited at higher concentrations due to competition
with ATP at the catalytic site on the α subunit. However, when
the assays were performed at 5 mM rather than 200 μM ATP
both the activating and the inhibiting phases of the curves were
shifted to the right by more than one order of magnitude (compare
Figures 3A and 3B). These findings mirror our previous findings
using rat liver AMPK (a mixture of the α1β1γ 1 and α2β1γ 1
isoforms) and are consistent with the idea that ATP antagonizes
the effect of AMP not only at the site(s) on the γ subunit
where it causes allosteric activation, but also at the catalytic site
Figure 2 Activation of FLAG–γ 1, –γ 2 or –γ 3 by various AMPK activators
Cells expressing FLAG–γ 1, –γ 2 or –γ 3 were incubated with DMSO (vehicle), phenformin
(10 mM), berberine (300 μM), A23187 (10 μM) or A-769662 (300 μM) for 60 min, AMPK
complexes were immunoprecipitated using anti-FLAG antibodies and were analysed by kinase
assays (upper panel) and Western blotting (lower panel). In the upper panel, results are means +−
S.D. (n =3); mean values significantly different from the DMSO control for each isoform (two-way
ANOVA with Dunnett’s multiple comparison test) are indicated: **P < 0.01; ***P < 0.001;
****P < 0.0001. The absolute activities (nmol/min/mg of lysate protein) in the DMSO
controls were: 0.16 +− 0.01 (γ 1), 0.24 +− 0.01 (γ 2) and 0.053 +− 0.001 (γ 3; means +− S.E.M.,
n = 3).
where (at higher concentrations) AMP causes inhibition [28].
Fitting the data to an equation assuming a single activating site
and a single inhibitory site yielded the following parameters
(means +− S.E.M.) with assays performed at 200 μM ATP:
γ 1 complex, activation, 3.9 +− 0.5-fold; concentration of AMP
giving half-maximal activation (EC50) 15 +− 5 μM; concentration
of AMP giving half-maximal inhibition (IC50) 0.66 +− 0.28 mM;
γ 2 complex, activation, 7.8 +− 1.0-fold; EC50, 16 +− 4 μM; IC50,
0.34 +− 0.09 mM; γ 3 complex, activation, 1.9 +− 0.1-fold; EC50,
5.5 +− 2.1 μM; IC50, 0.73 +− 0.22 mM. Thus, at 200 μM ATP,
activation was greatest with the γ 2 complex (8-fold), was less
with the γ 1 complex (4-fold) and was smallest (1.9-fold) with the
γ 3 complex. When the assays were conducted with 5 mM ATP
the following parameters were obtained: γ 1 complex, activation,
10 +− 2-fold; EC50, 120 +− 20 μM; IC50, 22 +− 5 mM; γ 2 complex,
activation, 9 +− 1-fold; EC50, 160 +− 30 μM; IC50, 29 +− 6 mM;
γ 3 complex, activation, 1.4 +− 0.03-fold; EC50, 12 +− 5 μM; IC50,
29 +− 6 mM. Thus, when measured at this more physiological
concentration of ATP, allosteric activation by AMP of both
the γ 1 and the γ 2 complexes increased to ∼10-fold, whereas
activation of the γ 3 complex became almost negligible (1.4-fold).
In addition, the EC50 values for allosteric activation by AMP of
the γ 1 and γ 2 complexes were ∼10-fold higher at the higher
ATP concentration (120 and 160 μM at 5 mM ATP, compared
with 15 and 16 μM at 200 μM ATP), whereas the IC50 values for
inhibition were 30–100-fold higher (22 and 29 mM at 5 mM ATP,
compared with 0.66 and 0.34 mM at 200 μM ATP). This reflects
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Figure 3 Allosteric activation of AMPK-γ isoforms at different
concentrations of ATP
Cells expressing FLAG–γ 1, –γ 2 or –γ 3 were treated with 10 mM phenformin for 60 min to
activate AMPK and the different complexes were immunoprecipitated using anti-FLAG antibody.
Kinase assays were conducted at the indicated concentrations of AMP, but with ATP at 200 μM
(A), 5 mM (B) or 20 μM (C). MgCl2 was also present at a concentration 4.8 mM higher than
ATP; this protocol results in the proportions present as free ATP and as the MgATP2 − complex
remaining approximately constant [55]. Results (means +− S.E.M., n = 3) are expressed relative
to the basal activity without AMP and were fitted to the equation: Y = 1 + {[(activation –
1) × X]/(EC50 + X)} – {[(activation) × X]/(IC50 + X)}, where Y is the activity, X is the
concentration of AMP, activation is the predicted maximal activation for the activating phase
of the curve, EC50 is the concentration of AMP causing half-maximal activation, and IC50 is
the concentration of AMP causing half-maximal inhibition. The continuous lines are the curves
generated by this equation using the values for activation, EC50 and IC50 quoted in the text.
the fact, as shown previously with rat liver AMPK [28], that AMP
and ATP compete for binding not only at the binding site(s) on the
γ subunits that cause allosteric activation, but also at the catalytic
site where AMP binding causes inhibition.
Since there was more activation of the γ 3 complex at the
lower ATP concentration (200 μM), we repeated the assays
in the presence of ATP concentrations 10-fold lower again
(20 μM). Under these conditions (Figure 3C), maximal activation
of the γ 1 and γ 2 complexes was lower than it was at higher
concentrations of ATP, but maximal activation of the γ 3 complex
increased, although it was still significantly less than that
of the other two. Fitting of the data yielded the following
parameters: γ 1, activation, 4.2 +− 1.3-fold; EC50, 7.0 +− 1.3 μM;
IC50, 0.58 +− 0.09 mM; γ 2, activation, 3.5 +− 0.2-fold; EC50,
4.2 +− 1.2 μM; IC50, 0.65 +− 0.15 mM; γ 3, activation, 2.0 +− 0.1-
fold; EC50, 1.4 +− 0.5 μM; IC50, 1.2 +− 0.3 mM.
Allosteric activation of bacterially expressed AMPK complexes
In order to confirm our results using complexes with a more
well-defined isoform composition, we expressed the human
α1β1γ 1, α2β2γ 1 and α2β2γ 3 complexes in bacteria, purified
them on Ni2 + –Sepharose and phosphorylated Thr172 using
CaMKKβ. Figure 4(A) shows Coomassie Blue-stained gels
of these preparations, whereas Figure 4(B) shows that, when
assayed at 5 mM ATP, the α1β1γ 1 and α2β2γ 1 complexes
were allosterically activated to similar extents by AMP,
although activation was more potent for the α2β2γ 1 complex
(α2β2γ 1: activation, 2.9 +− 0.1-fold; EC50, 16 +− 1 μM; α1β1γ 1:
activation, 3.2 +− 0.1-fold; EC50, 83 +− 7 μM). However, the
α2β2γ 3 complex was barely activated at all (<15%) by
AMP; this is similar to the results we obtained with γ 1 and
γ 3 complexes expressed in HEK-293 cells (Figure 3), except
that maximal activation by AMP was much smaller with the
bacterially expressed γ 1 complexes (∼3-fold) compared with
those expressed in mammalian cells (9–10-fold). We have
observed this difference consistently, which it is why we used the
mammalian expression system for the remaining studies described
in the present paper.
Promotion of LKB1-dependent activation and Thr172
phosphorylation by AMP
We next tested whether AMP promoted Thr172 phosphorylation
by LKB1, using complexes containing γ 1, γ 2 or γ 3 expressed
in HEK-293 cells and isolated using anti-FLAG antibody. The
IPs were treated with the protein phosphatase-1 catalytic subunit
(PP1γ ) to remove phosphate from Thr172, were washed to remove
PP1γ , and okadaic acid was added to block the activity of
any residual phosphatase. They were then treated with limiting
quantities of LKB1 in the presence of 5 mM ATP (to mimic
physiological conditions), with or without 1 mM AMP. This
revealed (Figure 5A) that AMP caused a 4-fold stimulation of
activation of the γ 1 complex, whereas the effects of AMP on the
γ 2 and γ 3 complexes were much smaller (<2-fold), although still
significant. Figure 5(B) shows the promotion of activation and
Thr172 phosphorylation of the γ 1 complex by LKB1 at various
concentrations of AMP, once again with 5 mM ATP in the assays.
Maximal activation was estimated to be 5.1 +− 1.3-fold and the
half-maximal effect of AMP was at 130 +− 50 μM, very similar
to the EC50 obtained for allosteric activation by AMP under the
same conditions (120 +− 20 μM).
We also tested whether AMP promoted AMPK activation
and Thr172 phosphorylation by CaMMKβ as well as LKB1, as
proposed previously [29]. The experiment was similar to that
shown in Figure 5(A) except that we also used a limiting amount of
CaMKKβ that gave a similar degree of Thr172 phosphorylation and
activation to that of LKB1. Figure 5(C) shows that, using LKB1
as the upstream kinase, AMP caused a substantial promotion of
AMPK activation as well as Thr172 phosphorylation, with smaller
effects on the γ 2 and γ 3 complexes, as in Figure 5(A). However,
AMP did not promote AMPK activation or Thr172 phosphorylation
by CaMKKβ using any of the γ subunit isoforms.
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
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Figure 4 Composition and allosteric activation of bacterially expressed
AMPK complexes
(A) Analysis of α1β1γ 1, α2β2γ 1 and α2β2γ 3 complexes by SDS/PAGE and Coomassie
Blue staining; (B) allosteric activation of α1β1γ 1, α2β2γ 1 and α2β2γ 3 complexes by AMP.
Assays in (B) were performed in the presence of 5 mM ATP and 9.8 mM MgCl2 and the data
fitted to the same equation as in Figure 3. Note added in proof : The band marked “?” in (A) has
been identified by mass fingerprinting to be the bacterial protein arnA (UNIPROT P77398).
Promotion of LKB1-dependent activation and Thr172
phosphorylation by ADP
Using native AMPK purified from rat liver (a mixture of the
α1β1γ 1 and α2β1γ 1 complexes), we previously reported small
effects of ADP on activation and Thr172 phosphorylation by LKB1
[28]. However, we suspected at that time that this was due to
breakdown of ADP to AMP during the assay, because the effect of
ADP appeared to be abolished by addition of the 5′-nucleotidase,
CD73, which degrades AMP but not ADP. We addressed this
question again using our immunoprecipitated human γ 1, γ 2
and γ 3 complexes (Figure 6). As before, AMP gave a large
stimulation of activation and Thr172 phosphorylation with the γ 1
complex and smaller effects with the γ 2 and γ 3 complex and
all of these effects were abolished by the inclusion of CD73 in
the assays as expected. ADP also appeared to cause a small
stimulatory effect with the γ 1 complex, although any effects on
the γ 2 and γ 3 complexes were not significant. Unexpectedly,
however, CD73 did not completely abolish the small stimulatory
effect of ADP on the γ 1 complex, suggesting that the effect
Figure 5 Effect of AMP on activation and Thr172 phosphorylation of AMPK-γ
isoforms induced by upstream kinases
(A) Effect of a limiting quantity of LKB1, with or without AMP (1 mM), on AMPK activity.
Anti-FLAG IPs from AMPK-γ 1-, -γ 2- or -γ 3-expressing cells were treated with PP1γ to
bring about complete dephosphorylation of Thr172. PP1γ was removed by washing and okadaic
acid was added to ensure complete inhibition of any residual phosphatase. The IPs were
then incubated for 10 min with 5 mM ATP with or without LKB1 (1 μg) and with or without
1 mM AMP. Results are means +− S.E.M. (n = 6) and mean values significantly different from
controls with LKB1 but without AMP (two-way ANOVA with Dunnett’s multiple comparison test)
are indicated (****P < 0.0001). (B) Effect of different concentrations of AMP on activation
and Thr172 phosphorylation of the AMPK-γ 1 complex. Experiment as in (A) except using
various concentrations of AMP in the presence of 5 mM ATP. Results in the upper panel
(means +− S.E.M., n = 6) are expressed relative to the control without AMP. Results were
fitted to the equation: Y = 1 + [(activation – 1) × X]/(EC50 + X), where Y is the relative
activity, X is the concentration of AMP, activation is the predicted maximal activation, and
EC50 is the concentration of AMP causing half-maximal activation. The continuous line is the
curve generated using this equation with the parameters quoted in the text. The lower panel
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was at least partly caused by binding of ADP, rather than by
breakdown of ADP to AMP during the assay. The Western blots
in Figure 6(B) confirm that the stimulatory effect of AMP on Thr172
phosphorylation induced by LKB1 was completely abolished by
addition of CD73, whereas the stimulatory effect of ADP was only
partly abolished. Any effects of ADP on Thr172 phosphorylation
by LKB1 of the γ 2 and γ 3 complexes were not detectable,
although there were small effects of AMP that were abolished by
CD73.
Figure 6(C) shows the concentration dependence for the effect
of ADP on activation by LKB1 using the γ 1 complex, whereas
Figure 6(D) shows Thr172 phosphorylation assessed by Western
blotting in the same experiment. Concentrations of ADP from
0.1 to 1 mM caused a small stimulatory effect, but above 1 mM
ADP caused a marked inhibition. It was not possible to obtain
precise estimates of the EC50 for the activating effect or the IC50
for the inhibitory effect, because the ranges of concentrations over
which they occurred were so similar. However, the EC50 for the
activating effect of ADP appeared to be at least 1 mM, which is
an order of magnitude higher than the EC50 for the effect of AMP
(130 μM).
Protection against dephosphorylation of Thr172 by AMP and ADP
Finally, we addressed the effects of AMP and ADP on the
dephosphorylation of γ 1, γ 2 and γ 3 complexes by the protein
phosphatase PP2Cα. Cells expressing γ 1, γ 2 or γ 3 complexes
were treated with phenformin to promote Thr172 phosphorylation,
the complexes were then isolated by immunoprecipitation and
equal amounts (based on anti-FLAG blots) were treated with
a limiting quantity of PP2Cα in the presence of increasing
concentrations of AMP or ADP. As before, in order to simulate
physiological conditions, these assays were performed in the
presence of 5 mM ATP. The upper panel of Figure 7(A) shows
that inactivation of all three complexes was protected in a very
similar manner by AMP, with the half-maximal effects occurring
at 170 +− 30 (γ 1), 130 +− 20 (γ 2) and 120 +− 30 μM (γ 3). The
similar effects of AMP on all three complexes were confirmed by
Western blot analysis using anti-pThr172 antibodies (lower panel).
The effects of ADP are shown in Figure 7(B); similar to results
previously obtained with rat liver AMPK [28] (which contains
exclusively the γ 1 isoform), with the γ 1 and γ 3 complexes we
found that the curves were shifted rightward, compared with those
for AMP, by almost one order of magnitude. This indicates that
ADP has a less potent protective effect than AMP, which was
reflected in the IC50 values: 170 +− 30 μM (AMP) and 910 +− 70(ADP) for γ 1 and 120 +− 30 μM (AMP) and 980 +− 150 (ADP)
for γ 3. However, a striking difference with the γ 2 complex
was that ADP was almost equally potent in protecting against
inactivation and Thr172 dephosphorylation as AMP. In this case,
the IC50 values were 130 +− 20 μM (AMP) and 180 +− 20 (ADP).
The upper panel of Figure 7(B) shows that the curve for protection
of γ 2 complexes by ADP was clearly different from those for the
γ 1 and γ 3 complexes and this difference can also be discerned in
the anti-pThr172 blots (lower panel).
shows duplicate Western blots from the same experiment. (C) As (A), except that we also tested
the effects of 1 mM AMP on activation by CaMKKβ as well as LKB1. The amount of CaMKKβ
added (0.34 μg) yielded a similar limited degree of activation to LKB1. Results significantly
different from the controls without AMP, by two-way ANOVA with Tukey’s multiple comparison
test, are indicated: *P < 0.05, ***P < 0.001, ****P < 0.0001. The lower panel shows Western
blots of single samples from the same experiment.
Figure 6 Effect of ADP on activation and Thr172 phosphorylation of AMPK-γ
isoforms induced by upstream kinases
(A) Effect of AMP or ADP on activation of γ 1-, γ 2- or γ 3-containing AMPK complexes induced
by LKB1 in the presence of 5 mM ATP. Dephosphorylated AMPK complexes were generated as
in Figure 3(A) and were incubated for 10 min with LKB1 with or without AMP (300 μM), ADP
(1 mM) or the 5′-nucleotidase CD73 (0.86 μg). Results are means +− S.E.M. (n = 4) and results
significantly different with/without AMP or ADP (*P < 0.05; ****P < 0.0001) and with/without
CD73 (†††P < 0.001, ††††P < 0.0001), determined by two-way ANOVA with Tukey’s multiple
comparison test, are indicated. (B) Duplicate blots from the experiment shown in (A). (C) Effect
of ADP on activation of AMPK-γ 1 complexes by LKB1 in the presence of 5 mM ATP. The
experiment was performed as in (A) except with various concentrations of ADP. Results (means
+− S.E.M., n = 3) are expressed relative to the basal activity in the absence of ADP and were
fitted to the equation used for Figure 3(B). The continuous line is the curve generated using the
best-fit parameters (activation= 5-fold, EC50 = 1.8 +− 1.1 mM; IC50 = 6.8 +− 3.1 mM; activation
was constrained to be 5-fold or less). However, the confidence limits for these parameters are
extremely wide because the activating and inhibitory phases of the curve are so close together.
(D) Duplicate blots obtained from the experiment shown in (C).
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Figure 7 Effect of AMP and ADP on protection against Thr172
dephosphorylation, measured at 5 mM ATP
(A) AMP-γ 1, -γ 2 or -γ 3 complexes were immunoprecipitated from cells treated with
phenformin to cause maximal Thr172 phosphorylation. The IPs were then incubated for 10 min
with the protein phosphatase PP2Cα in the presence of 5 mM ATP and various concentrations
of AMP. Inactivation was assessed by kinase assays (top panel) and Thr172 dephosphorylation
by Western blot (bottom panels). Results (means +− S.E.M., n = 2) in the top panel are shown as
percentage protection, which is the inactivation compared with control (without AMP), expressed
as a percentage of the inactivation compared with control at the highest concentration of AMP
used. Results were fitted to the equation Y = 100 × X/(EC50 + X) where Y is the percentage
protection, X is the concentration of AMP, and EC50 is the concentration of AMP causing
half-maximal protection. The continuous lines are the curves generated using this equation
using the best-fit parameters quoted in the text. The lower panel shows single Western blot blots
for each condition, with the increasing concentrations of AMP being 30 μM, 100 μM, 300 μM,
1 mM, 3 mM and 10 mM. (B) As (A), but varying ADP in place of AMP.
DISCUSSION
Our results clearly demonstrate that human AMPK complexes
containing the γ 1, γ 2 or γ 3 isoforms, when expressed in human
cells, differ in several respects in their responses to adenine
nucleotide. These differences can be summarized as follows:
(i) Complexes containing γ 1 and γ 2 were allosterically
activated by AMP up to 10-fold, with half-maximal effects
(measured in the presence of 5 mM ATP) at 120 (γ 1) and 160 μM
(γ 2), which are 30–40-fold lower than the concentration of ATP
utilized in the assay (5 mM). By contrast, γ 3 complexes were
only significantly allosterically activated by AMP (2-fold) at
very low ATP concentrations (20 μM) that are unlikely to be
physiologically relevant.
(ii) Activation of γ 1 complexes caused by Thr172 phosphoryla-
tion was stimulated >4-fold by AMP when LKB1, but not
CaMKKβ, was the upstream kinase. Much smaller (<2-fold),
although still significant, effects of AMP were observed using γ 2
and γ 3 complexes. The half-maximal effect of AMP on activation
of γ 1 complexes by LKB1, measured at 5 mM ATP (130 μM),
was very similar to the half-maximal effect for allosteric activation
(120 μM).
(iii) Activation of γ 1 complexes caused by Thr172 phosphoryla-
tion by LKB1 was also stimulated ∼2-fold by ADP, although we
did not observe this effect with γ 2 or γ 3 complexes. Despite our
earlier findings with native AMPK from rat liver [28], this effect
of ADP could not be completely explained by its breakdown
in the assay to AMP, because it was only partially abolished
by addition of the 5′-nucleotidase CD73. However, the effect
did require ADP concentrations an order of magnitude higher
than AMP and at concentrations only slightly higher again, ADP
markedly inhibited activation.
(iv) Inactivation of all three γ complexes by Thr172
dephosphorylation, catalysed by PP2Cα, was reduced by
AMP binding. The concentrations of AMP causing half-
maximal effects, measured at 5 mM ATP, were similar for
all three complexes (120–170 μM) and were similar to
the concentrations causing half-maximal allosteric activation
with γ 1 and γ 2 complexes and half-maximal activation of
phosphorylation/activation by LKB1 using γ 1 complexes. All
of these effects were measured in the presence of a physiologically
relevant concentration of ATP (5 mM).
(v) Inactivation of all three γ complexes by Thr172
dephosphorylation catalysed by PP2Cα was also protected
by binding of ADP. Interestingly, however, the concentrations
causing half-maximal effects, measured at 5 mM ATP, were
similar for AMP and ADP using γ 2 complexes (130 and 180 μM),
but those for ADP were almost an order of magnitude higher than
those for AMP using γ 1 and γ 3 complexes. Thus AMP is in
general a more potent activator of AMPK than ADP, with the
interesting exception of the γ 2 complex.
The AMPK activity in HEK-293 cells is largely accounted
for by the α1, β1, β2 and γ 1 isoforms [49], although in the
cells we studied the expressed γ 1, γ 2 and, to a lesser extent, γ 3
subunits replaced the endogenous γ 1 (Figure 1A). Complexes
containing endogenous γ 1 would not have been present in our
IPs because they would not be FLAG-tagged. However, we
chose not to study effects on any downstream targets such as
ACC1 in the intact cells, because such results might have been
compromised by the presence in the cells of complexes containing
endogenous γ 1. The complexes isolated from HEK-293 cells
would have predominantly been the α1β2γ 1, α1β2γ 2 or α1β2γ 3
complexes, although the anti-FLAG IPs also contained some
α2 and β1 and there may have been minor contributions from
those isoforms. It was not feasible to confirm the purity of the
complexes in the IPs by Coomassie Blue staining due to its lack
of sensitivity, so we cannot exclude the possibility that other
proteins associating with the AMPK heterotrimer might have
influenced the results. However, the results obtained with the
bacterially expressed α1β1γ 1, α2β2γ 1 and α2β2γ 3 complexes
in Figure 4(B) suggest that it is indeed the identity of the γ subunit
isoform that determines the allosteric response to AMP, in that
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the α1β1γ 1 and α2β2γ 1 complexes were clearly activated by
AMP when the assays were performed in the presence of 5 mM
ATP, whereas activation of the α2β2γ 3 complex was minimal.
The α2β2γ 3 complex is the only complex found to be activated
by contraction in skeletal muscle, although since activation was
measured after immunoprecipitation [8], it must have been due to
increased Thr172 phosphorylation rather than any allosteric effect.
It is indeed notable that the complex that is activated by muscle
contraction is not subject to allosteric activation.
It remains unclear as to why the allosteric activation by AMP
of γ 1 and γ 2 complexes is much greater for those expressed
in mammalian cells rather than in bacteria, although we suspect
that it may be due to some covalent modification (other than
Thr172 phosphorylation) that occurs in mammalian cells but not
in bacteria. Since the regulation of the bacterially expressed
complexes is in that sense abnormal, we chose to study the other
regulatory mechanisms only with the complexes expressed in
human cells.
In 2011, it was reported that ADP was almost as effective
as AMP in promoting Thr172 phosphorylation on AMPK, using
CaMKKβ as the upstream kinase [29]. Using native AMPK
purified from rat liver (a mixture of the α1β1γ 1 and α2β1γ 1
complexes) we reported that ADP did stimulate activation and
Thr172 phosphorylation by LKB1, but not by CaMKKβ. However,
we suspected that this effect of ADP was caused by its breakdown
in the assay to AMP, because it appeared to be abolished by
the addition of CD73, a 5′-nucleotidase that hydrolyses AMP to
adenosine, but has no effect on ADP. In the present study, we
observed small effects of activation and Thr172 phosphorylation
of γ 1 complexes by ADP and these effects were reduced but not
abolished by CD73. The CD73 was clearly functional in the assay
because it did abolish the effects of AMP (Figures 6A and 6B).
The effects of ADP could not therefore be entirely explained by
breakdown of ADP to AMP in the assay. Despite this, we suspect
that the stimulatory effect of ADP on activation of γ 1 complexes
might not have much physiological relevance. The effect is only
observed with γ 1 complexes, is small (<2-fold) and requires high
concentrations of ADP (>1 mM). Moreover, at concentrations of
ADP only slightly higher again (10 mM), ADP caused a marked
inhibition to well below the basal activity (Figure 6C and 6D).
At this concentration, ADP is higher than ATP in the assay and it
may simply inhibit the upstream kinase LKB1 by competing with
ATP at the catalytic site. Thus, there is only a narrow window
of concentrations where ADP might have a stimulatory effect on
Thr172 phosphorylation by LKB1.
What is the reason for the discrepancy between our results,
in which AMP binding did not promote activation and Thr172
phosphorylation of γ 1 complexes by CaMKKβ and those of
others who reported that AMP does promote activation
of an α1β1γ 1 complex (expressed in COS7 cells) by CaMKKβ
[29]? One possible explanation is that in the latter study the
α1β1γ 1 complex had been expressed with a GST-tag on
the α1 subunit. The complex was dephosphorylated on
glutathione–Sepharose beads using recombinant PP2Cα and
the “beads were washed extensively before elution” prior to
performing the phosphorylation experiment. However, the PP2Cα
used, which was expressed in Sf9 insect cells, had also been GST-
tagged and was purified on glutathione–Sepharose [52]. Although
the GST tag was “completely removed from PP2C by tobacco
etch virus protease treatment” if there was any residual uncleaved
GST-tag or the washing did not remove all of the phosphatase,
then their final preparation of dephosphorylated AMPK might
have been contaminated with PP2Cα. The apparent effects of
AMP to promote Thr172 phosphorylation might then have been
caused by the ability of AMP to inhibit dephosphorylation. We
avoided this potential problem by dephosphorylating AMPK in
the IP using PP1γ rather than PP2Cα, by washing the precipitates
extensively and by adding the PPP family phosphatase inhibitor,
okadaic acid [53], to the phosphorylation reaction to inhibit any
traces of residual PP1γ .
The molecular mechanisms for the differential effects of AMP,
ADP and ATP on AMPK complexes containing the γ 1, γ 2 and γ 3
isoforms remain unclear at present. All existing crystal structures
for core [24,26] or full-length [18,20,27,54] heterotrimers with
bound adenine nucleotides contain only the γ 1 isoform and
the exact roles of the three nucleotide-binding sites in the
three mechanisms of regulation remain poorly understood. The
sequences of the CBS repeats in the γ 1, γ 2 and γ 3 isoforms are
highly conserved, but it seems possible that subtle differences in
the affinities of sites 1, 3 and 4 for AMP, ADP and ATP could
explain the differences in regulation reported in the present study.
The major differences in the sequences of the γ subunit isoforms
lie in their N-terminal regions, with γ 2 and γ 3 having N-terminal
extensions of approximately 250 and 180 residues respectively,
which are unrelated to each other and are not present in γ 1;
both γ 2 and γ 3 also occur as shorter variants [35,36]. Although
the functions of these N-terminal extensions remain uncertain,
there is evidence that different isoform combinations are found
at different subcellular locations [30,35,37] and it seems possible
that the N-terminal extensions are involved in targeting of AMPK
to specific subcellular locations. The only cell type that clearly
expresses all three isoforms of the γ subunit is skeletal muscle,
where compartmentation may be a particular issue due to the
abundance of the contractile machinery. It is tempting to propose
that the differential responses to AMP, ADP and ATP of AMPK
complexes containing distinct γ subunit isoforms may allow the
fine-tuning of responses to energy stress in specific subcellular
locations, especially in muscle. However, any detailed discussion
of the potential physiological role of these findings would only be
speculative at present.
AUTHOR CONTRIBUTION
Fiona Ross designed and carried out experiments and generated novel cell lines used
in the present study. Grahame Hardie supervised experiments and provided advice. All
authors contributed in writing the manuscript.
ACKNOWLEDGEMENTS
We are very grateful to the Division of Signal Transduction Therapy (University of Dundee),
Anu Balendran of AstraZeneca and Ravi Kurumbail and Francis Rajamohan of Pfizer, for
the constructs for bacterial expression of AMPK heterotrimers.
FUNDING
This work was supported by the Wellcome Trust [grant number 097726 (to D.G.H and
F.A.R.)], AstraZeneca, Boehringer-Ingelheim, GlaxoSmithKline, Merck KgaA, Janssen
Pharmaceutica and Pfizer.
REFERENCES
1 Hardie, D.G. (2014) AMPK - sensing energy while talking to other signaling pathways.
Cell Metab. 20, 939–952 CrossRef PubMed
2 Hardie, D.G. (2014) AMP-activated protein kinase: maintaining energy homeostasis at the
cellular and whole-body levels. Annu. Rev. Nutr. 34, 31–55 CrossRef PubMed
3 Hardie, D.G. (2014) AMPK: positive and negative regulation, and its role in whole-body
energy homeostasis. Curr. Opin. Cell Biol. 33, 1–7 CrossRef PubMed
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
198 F.A. Ross, T.E. Jensen and D.G. Hardie
4 Stapleton, D., Mitchelhill, K.I., Gao, G., Widmer, J., Michell, B.J., Teh, T., House, C.M.,
Fernandez, C.S., Cox, T., Witters, L.A. and Kemp, B.E. (1996) Mammalian AMP-activated
protein kinase subfamily. J. Biol. Chem. 271, 611–614 CrossRef PubMed
5 Thornton, C., Snowden, M.A. and Carling, D. (1998) Identification of a novel
AMP-activated protein kinase b subunit isoform which is highly expressed in skeletal
muscle. J. Biol. Chem. 273, 12443–12450 CrossRef PubMed
6 Cheung, P.C. F., Salt, I.P., Davies, S.P., Hardie, D.G. and Carling, D. (2000)
Characterization of AMP-activated protein kinase g subunit isoforms and their role in
AMP binding. Biochem. J. 346, 659–669 CrossRef PubMed
7 Hudson, E.R., Pan, D.A., James, J., Lucocq, J.M., Hawley, S.A., Green, K.A., Baba, O.,
Terashima, T. and Hardie, D.G. (2003) A novel domain in AMP-activated protein kinase
causes glycogen storage bodies similar to those seen in hereditary cardiac arrhythmias.
Curr. Biol. 13, 861–866 CrossRef PubMed
8 Birk, J.B. and Wojtaszewski, J.F. (2006) Predominant alpha-1/beta-2/gamma-3 AMPK
activation during exercise in human skeletal muscle. J. Physiol. 577, 1021–1032
CrossRef PubMed
9 Hawley, S.A., Davison, M., Woods, A., Davies, S.P., Beri, R.K., Carling, D. and Hardie,
D.G. (1996) Characterization of the AMP-activated protein kinase kinase from rat liver, and
identification of threonine-172 as the major site at which it phosphorylates and activates
AMP-activated protein kinase. J. Biol. Chem. 271, 27879–27887 CrossRef PubMed
10 Woods, A., Johnstone, S.R., Dickerson, K., Leiper, F.C., Fryer, L.G., Neumann, D.,
Schlattner, U., Wallimann, T., Carlson, M. and Carling, D. (2003) LKB1 is the upstream
kinase in the AMP-activated protein kinase cascade. Curr. Biol. 13, 2004–2008
CrossRef PubMed
11 Shaw, R.J., Kosmatka, M., Bardeesy, N., Hurley, R.L., Witters, L.A., DePinho, R.A. and
Cantley, L.C. (2004) The tumor suppressor LKB1 kinase directly activates AMP-activated
kinase and regulates apoptosis in response to energy stress. Proc. Natl. Acad. Sci. U.S.A.
101, 3329–3335 CrossRef PubMed
12 Hawley, S.A., Boudeau, J., Reid, J.L., Mustard, K.J., Udd, L., Makela, T.P., Alessi, D.R. and
Hardie, D.G. (2003) Complexes between the LKB1 tumor suppressor, STRADa/b and
MO25a/b are upstream kinases in the AMP-activated protein kinase cascade. J. Biol. 2,
28 CrossRef PubMed
13 Woods, A., Dickerson, K., Heath, R., Hong, S.P., Momcilovic, M., Johnstone, S.R.,
Carlson, M. and Carling, D. (2005) Ca2 + /calmodulin-dependent protein kinase
kinase-beta acts upstream of AMP-activated protein kinase in mammalian cells. Cell
Metab. 2, 21–33 CrossRef PubMed
14 Hurley, R.L., Anderson, K.A., Franzone, J.M., Kemp, B.E., Means, A.R. and Witters, L.A.
(2005) The Ca2 + /calmoldulin-dependent protein kinase kinases are AMP-activated
protein kinase kinases. J. Biol. Chem. 280, 29060–29066 CrossRef PubMed
15 Hawley, S.A., Pan, D.A., Mustard, K.J., Ross, L., Bain, J., Edelman, A.M., Frenguelli, B.G.
and Hardie, D.G. (2005) Calmodulin-dependent protein kinase kinase-beta is an
alternative upstream kinase for AMP-activated protein kinase. Cell Metab. 2, 9–19
CrossRef PubMed
16 Polekhina, G., Gupta, A., Michell, B.J., van Denderen, B., Murthy, S., Feil, S.C., Jennings,
I.G., Campbell, D.J., Witters, L.A. and Parker, M.W. (2003) AMPK b-Subunit targets
metabolic stress-sensing to glycogen. Curr. Biol. 13, 867–871 CrossRef PubMed
17 Polekhina, G., Gupta, A., van Denderen, B.J., Feil, S.C., Kemp, B.E., Stapleton, D. and
Parker, M.W. (2005) Structural basis for glycogen recognition by AMP-activated protein
kinase. Structure 13, 1453–1462 CrossRef PubMed
18 Xiao, B., Sanders, M.J., Carmena, D., Bright, N.J., Haire, L.F., Underwood, E., Patel, B.R.,
Heath, R.B., Walker, P.A., Hallen, S. et al. (2013) Structural basis of AMPK regulation by
small molecule activators. Nat. Commun. 4, 3017 PubMed
19 Hawley, S.A., Fullerton, M.D., Ross, F.A., Schertzer, J.D., Chevtzoff, C., Walker, K.J.,
Peggie, M.W., Zibrova, D., Green, K.A., Mustard, K.J. et al. (2012) The ancient drug
salicylate directly activates AMP-activated protein kinase. Science 336, 918–922
CrossRef PubMed
20 Calabrese, M.F., Rajamohan, F., Harris, M.S., Caspers, N.L., Magyar, R., Withka, J.M.,
Wang, H., Borzilleri, K.A., Sahasrabudhe, P.V., Hoth, L.R. et al. (2014) Structural basis for
AMPK activation: natural and synthetic ligands regulate kinase activity from opposite
poles by different molecular mechanisms. Structure 22, 1161–1172
CrossRef PubMed
21 Scott, J.W., Ling, N., Issa, S.M., Dite, T.A., O’Brien, M.T., Chen, Z.P., Galic, S.,
Langendorf, C.G., Steinberg, G.R., Kemp, B.E. and Oakhill, J.S. (2014) Small molecule
drug A-769662 and AMP synergistically activate naive AMPK independent of upstream
kinase signaling. Chem. Biol. 21, 619–627 CrossRef PubMed
22 Bateman, A. (1997) The structure of a domain common to archaebacteria and the
homocystinuria disease protein. Trends Biochem. Sci. 22, 12–13 CrossRef PubMed
23 Scott, J.W., Hawley, S.A., Green, K.A., Anis, M., Stewart, G., Scullion, G.A., Norman, D.G.
and Hardie, D.G. (2004) CBS domains form energy-sensing modules whose binding of
adenosine ligands is disrupted by disease mutations. J. Clin. Invest. 113, 274–284
CrossRef PubMed
24 Xiao, B., Heath, R., Saiu, P., Leiper, F.C., Leone, P., Jing, C., Walker, P.A., Haire, L.,
Eccleston, J.F., Davis, C.T. et al. (2007) Structural basis for AMP binding to mammalian
AMP-activated protein kinase. Nature 449, 496–500 CrossRef PubMed
25 Kemp, B.E., Oakhill, J.S. and Scott, J.W. (2007) AMPK structure and regulation from three
angles. Structure 15, 1161–1163 CrossRef PubMed
26 Chen, L., Wang, J., Zhang, Y.Y., Yan, S.F., Neumann, D., Schlattner, U., Wang, Z.X. and
Wu, J.W. (2012) AMP-activated protein kinase undergoes nucleotide-dependent
conformational changes. Nat. Struct. Mol. Biol. 19, 716–718 CrossRef PubMed
27 Xiao, B., Sanders, M.J., Underwood, E., Heath, R., Mayer, F.V., Carmena, D., Jing, C.,
Walker, P.A., Eccleston, J.F., Haire, L.F. et al. (2011) Structure of mammalian AMPK and
its regulation by ADP. Nature 472, 230–233 CrossRef PubMed
28 Gowans, G.J., Hawley, S.A., Ross, F.A. and Hardie, D.G. (2013) AMP is a true
physiological regulator of AMP-activated protein kinase by both allosteric activation and
enhancing net phosphorylation. Cell Metab. 18, 556–566 CrossRef PubMed
29 Oakhill, J.S., Steel, R., Chen, Z.P., Scott, J.W., Ling, N., Tam, S. and Kemp, B.E. (2011)
AMPK is a direct adenylate charge-regulated protein kinase. Science 332, 1433–1435
CrossRef PubMed
30 Salt, I.P., Celler, J.W., Hawley, S.A., Prescott, A., Woods, A., Carling, D. and Hardie, D.G.
(1998) AMP-activated protein kinase - greater AMP dependence, and preferential nuclear
localization, of complexes containing the a2 isoform. Biochem. J. 334, 177–187
CrossRef PubMed
31 Turnley, A.M., Stapleton, D., Mann, R.J., Witters, L.A., Kemp, B.E. and Bartlett, P.F. (1999)
Cellular distribution and developmental expression of AMP-activated protein kinase
isoforms in mouse central nervous system. J. Neurochem. 72, 1707–1716
CrossRef PubMed
32 Ai, H., Ihlemann, J., Hellsten, Y., Lauritzen, H.P., Hardie, D.G., Galbo, H. and Ploug, T.
(2002) Effect of fiber type and nutritional state on AICAR- and contraction-stimulated
glucose transport in rat muscle. Am. J. Physiol. Endocrinol. Metab. 282, E1291–E1300
CrossRef PubMed
33 Kazgan, N., Williams, T., Forsberg, L.J. and Brenman, J.E. (2010) Identification of a
nuclear export signal in the catalytic subunit of AMP-activated protein kinase. Mol. Biol.
Cell 21, 3433–3442 CrossRef PubMed
34 Koay, A., Woodcroft, B., Petrie, E.J., Yue, H., Emanuelle, S., Bieri, M., Bailey, M.F.,
Hargreaves, M., Park, J.T., Park, K.H. et al. (2010) AMPK beta subunits display isoform
specific affinities for carbohydrates. FEBS Lett. 584, 3499–3503
CrossRef PubMed
35 Pinter, K., Grignani, R.T., Watkins, H. and Redwood, C. (2013) Localisation of AMPK
gamma subunits in cardiac and skeletal muscles. J. Muscle Res. Cell Motil. 34, 369–378
CrossRef PubMed
36 Yu, H., Fujii, N., Hirshman, M.F., Pomerleau, J.M. and Goodyear, L.J. (2004) Cloning and
characterization of mouse 5’-AMP-activated protein kinase gamma3 subunit. Am. J.
Physiol. Cell Physiol. 286, C283–C292 CrossRef PubMed
37 Pinter, K., Jefferson, A., Czibik, G., Watkins, H. and Redwood, C. (2012) Subunit
composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug
target identification. Cell Cycle 11, 917–921 CrossRef PubMed
38 Corton, J.M., Gillespie, J.G., Hawley, S.A. and Hardie, D.G. (1995)
5-Aminoimidazole-4-carboxamide ribonucleoside: a specific method for activating
AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558–565
CrossRef PubMed
39 Jensen, T.E., Ross, F.A., Kleinert, M., Sylow, L., Knudsen, J.R., Gowans, G.J., Hardie, D.G.
and Richter, E.A. (2015) PT-1 selectively activates AMPK-gamma1 complexes in mouse
skeletal muscle, but activates all three gamma subunit complexes in cultured human cells
by inhibiting the respiratory chain. Biochem. J. 467, 461–472 CrossRef PubMed
40 Pang, T., Zhang, Z.S., Gu, M., Qiu, B.Y., Yu, L.F., Cao, P.R., Shao, W., Su, M.B., Li, J.Y.,
Nan, F.J. and Li, J. (2008) Small molecule antagonizes autoinhibition and activates
AMP-activated protein kinase in cells. J. Biol. Chem. 283, 16051–16060
CrossRef PubMed
41 Iyengar, R.R., Judd, A.S., Zhao, G., Kym, P.R., Sham, H.L., Gu, Y., Liu, G., Zhao, H., Clark,
R.E., Frevert, E.U. et al. (2005) Thienopyridines as AMPK activators for the treatment of
diabetes and obesity., U.S. Pat. 20050038068 A1
42 Jaleel, M., Villa, F., Deak, M., Toth, R., Prescott, A.R., Van Aalten, D.M. and Alessi, D.R.
(2006) The ubiquitin-associated domain of AMPK-related kinases regulates conformation
and LKB1-mediated phosphorylation and activation. Biochem. J. 394, 545–555
CrossRef PubMed
43 Davies, S.P., Helps, N.R., Cohen, P.T. W. and Hardie, D.G. (1995) 5’-AMP inhibits
dephosphorylation, as well as promoting phosphorylation, of the AMP-activated protein
kinase. Studies using bacterially expressed human protein phosphatase-2Ca and native
bovine protein phosphatase-2AC. FEBS Lett. 377, 421–425
CrossRef PubMed
44 Woods, A., Salt, I., Scott, J., Hardie, D.G. and Carling, D. (1996) The a1 and a2 isoforms
of the AMP-activated protein kinase have similar activities in rat liver but exhibit
differences in substrate specificity in vitro. FEBS Lett. 397, 347–351 CrossRef PubMed
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
Differential regulation of AMPK-γ isoforms 199
45 Auciello, F.R., Ross, F.A., Ikematsu, N. and Hardie, D.G. (2014) Oxidative stress activates
AMPK in cultured cells primarily by increasing cellular AMP and/or ADP. FEBS Lett. 588,
3361–3366 CrossRef PubMed
46 Hardie, D.G., Salt, I.P. and Davies, S.P. (2000) Analysis of the role of the AMP-activated
protein kinase in the response to cellular stress. Methods Mol. Biol. 99, 63–75 PubMed
47 Davies, S.P., Carling, D. and Hardie, D.G. (1989) Tissue distribution of the AMP-activated
protein kinase, and lack of activation by cyclic AMP-dependent protein kinase, studied
using a specific and sensitive peptide assay. Eur. J. Biochem. 186, 123–128
CrossRef PubMed
48 Dale, S., Wilson, W.A., Edelman, A.M. and Hardie, D.G. (1995) Similar substrate
recognition motifs for mammalian AMP-activated protein kinase, higher plant HMG-CoA
reductase kinase-A, yeast SNF1, and mammalian calmodulin-dependent protein kinase I.
FEBS Lett. 361, 191–195 CrossRef PubMed
49 Hawley, S.A., Ross, F.A., Chevtzoff, C., Green, K.A., Evans, A., Fogarty, S., Towler, M.C.,
Brown, L.J., Ogunbayo, O.A., Evans, A.M. and Hardie, D.G. (2010) Use of cells
expressing gamma subunit variants to identify diverse mechanisms of AMPK activation.
Cell Metab. 11, 554–565 CrossRef PubMed
50 Tokumitsu, H., Inuzuka, H., Ishikawa, Y., Ikeda, M., Saji, I. and Kobayashi, R. (2002)
STO-609, a specific inhibitor of the Ca2 + /calmodulin-dependent protein kinase kinase. J.
Biol. Chem. 277, 15813–15818 CrossRef PubMed
51 Goransson, O., McBride, A., Hawley, S.A., Ross, F.A., Shpiro, N., Foretz, M., Viollet, B.,
Hardie, D.G. and Sakamoto, K. (2007) Mechanism of action of A-769662, a valuable tool
for activation of AMP-activated protein kinase. J. Biol. Chem. 282, 32549–32560
CrossRef PubMed
52 Oakhill, J.S., Chen, Z.P., Scott, J.W., Steel, R., Castelli, L.A., Ling, N., Macaulay, S.L. and
Kemp, B.E. (2010) β-Subunit myristoylation is the gatekeeper for initiating metabolic
stress sensing by AMP-activated protein kinase (AMPK). Proc. Natl. Acad. Sci. U.S.A.
107, 19237–19241 CrossRef PubMed
53 Haystead, T.A. J., Sim, A.T. R., Carling, D., Honnor, R.C., Tsukitani, Y., Cohen, P. and
Hardie, D.G. (1989) Stimulation of protein phosphorylation and glucose transport in
intact cells by the tumour promoter okadaic acid. Nature 337, 78–81
CrossRef PubMed
54 Li, X., Wang, L., Zhou, X.E., Ke, J., de Waal, P.W., Gu, X., Tan, M.H., Wang, D., Wu, D.,
Xu, H.E. and Melcher, K. (2015) Structural basis of AMPK regulation by adenine
nucleotides and glycogen. Cell Res. 25, 50–66
CrossRef PubMed
55 Storer, A.C. and Cornish-Bowden, A. (1976) Concentration of MgATP2- and other
ions in solution. Calculation of the true concentrations of species present in
mixtures of associating ions. Biochem. J. 159, 1–5
CrossRef PubMed
Received 18 August 2015/26 October 2015; accepted 5 November 2015
Accepted Manuscript online 5 November 2015, doi:10.1042/BJ20150910
c© 2016 Authors. This is an open access article published by Portland Press Limited and distributed under the Creative Commons Attribution License 3.0.
